<DOC>
	<DOC>NCT00402038</DOC>
	<brief_summary>To determine the efficacy of subcutaneous MNTX to relieve opioid-induced constipation in patients with advanced medical illness.</brief_summary>
	<brief_title>Study of Methylnaltrexone (MNTX) for the Relief of Constipation</brief_title>
	<detailed_description>This is a multi-center, double-blind, randomized parallel group study conducted in patients with advanced medical illness and opioid-induced constipation. Eligible patients are randomly assigned to receive SC doses of either MNTX, dose 1 or placebo every other day for 2 weeks. At Day 8, eligible patients, if allowed, could be escalated to a a higher dose of MNTX.</detailed_description>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Methylnaltrexone</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>18 years of age and older Negative pregnancy test (serum or urine) at screening for all women of childbearing potential Advanced Medical Illness (i.e., terminal illness, such as incurable cancer or end of stage AIDS) with life expectancy of â‰¥ 1 month patient must sign ICF Women who are pregnant and/or nursing Previous treatment with MNTX Participation in any other studies involving investigational products within 30 days prior to screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
</DOC>